DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC)

CUSIP: 25253X207

Q1 2022 13F Holders as of 31 Mar 2022

Holder snapshot 7 signals
Share change
+11,186
Put/Call ratio
42%
SEC-reported price per share
$2.50
Number of holders
28
Value change
-$427,839
Number of buys
8
Open additional details 1 more signal available
Number of sells
19
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
52,272,727

Security key

25253X207

Report period

Q1 2022

Institutions

28

Top holders

10

Ownership snapshot

Top reported holders of DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Stonepine Capital Managem...
Disclosed value leader
Stonepine Capital Managem...
Comparable rows
0/15
Latest evidence
31 Dec 2021
13F Highest disclosed value: $4,456,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Stonepine Capital Management, LLC has the largest disclosed position value at $4.46M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Stonepine Capital Management, LLC's linked filing trail.
Disclosed position value Top 5
Stonepine Capital Management, LLC $4.46M
VANGUARD GROUP INC $2.93M
Leon G. Cooperman $1.12M
JACOB ASSET MANAGEMENT OF NEW YOR... $1.03M
Ikarian Capital, LLC $779K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Stonepine Capital Management, LLC
13F
Company
13F
—
denominator unverified
$4,456,000
1,194,670 shares
— 31 Dec 2021
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$2,934,000
786,552 shares
— 31 Dec 2021
Leon G. Cooperman
13F
Individual
13F
—
denominator unverified
$1,119,000
300,000 shares
— 31 Dec 2021
JACOB ASSET MANAGEMENT OF NEW YORK LLC
13F
Company
13F
—
denominator unverified
$1,026,000
275,000 shares
— 31 Dec 2021
Ikarian Capital, LLC
13F
Company
13F
—
denominator unverified
$779,000
209,082 shares
— 31 Dec 2021
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
13F
—
denominator unverified
$625,000
167,763 shares
— 31 Dec 2021
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
28
Shares
4,006,054
Rows available
28
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2022 vs Q1 2022 Across Filers

Q1 2022 holders
28
Q1 2022 holders
28
Holder diff
0
Investor Q1 2022 Shares Q1 2022 Shares Share Diff Share Chg % Q1 2022 value Q1 2022 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .